- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 209/12 - Radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 209/12
Total number of patents in this class: 637
10-year publication summary
61
|
52
|
45
|
48
|
63
|
28
|
39
|
27
|
45
|
11
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 5080 |
16 |
Vertex Pharmaceuticals Incorporated | 1581 |
15 |
Achillion Pharmaceuticals, Inc. | 176 |
14 |
Janssen Pharmaceuticals, Inc. | 399 |
11 |
The Johns Hopkins University | 5377 |
9 |
BioCryst Pharmaceuticals, Inc. | 170 |
9 |
Katholieke Universiteit Leuven | 1035 |
9 |
FUJIFILM Corporation | 27102 |
8 |
California Institute of Technology | 3884 |
8 |
Novartis AG | 11238 |
7 |
F. Hoffmann-La Roche AG | 7958 |
6 |
Toyama Chemical Co., Ltd. | 114 |
6 |
Versicolor Technologies, LLC | 10 |
6 |
The Regents of the University of California | 18943 |
5 |
Wyeth LLC | 691 |
5 |
The Board of Trustees of the University of Illinois | 2623 |
5 |
Jiangsu Hengrui Medicine Co., Ltd. | 780 |
5 |
Medivir AB | 142 |
5 |
Shanghai Hengrui Pharmaceutical Co., Ltd. | 588 |
5 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
5 |
Other owners | 478 |